Amylin Pharmaceuticals (AMLN) Reports Q1 Loss of 24c, Misses by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Financial Fact:
Total costs and expenses: 208.02M
Today's EPS Names:
JBLU, SICP, OMID, More
Financial Fact:
Total costs and expenses: 208.02M
Today's EPS Names:
JBLU, SICP, OMID, More
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q1 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $152.7 million versus the consensus estimate of $156.73 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
- Noble Corp (NE) Misses Q3 EPS by 81c; Offers Outlook
- German American Bancorp (GABC) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
Earnings, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
